Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsA first-of-its-kind wearable device for glaucoma patients just got a major boost. Medicare coverage for the Fsyx ocular pressure adjusting pump (OPAP) — pressure-sensing goggles that reduce intraocular pressure (IOP) overnight using negative pressure — became effective October 1. The device offers a non-drug, non-surgical option for patients whose eye pressure tends to spike at night, a time when many existing treatments fall short.
A novel overnight wearable for glaucoma just became more accessible. CMS reimbursement for the Fsyx ocular pressure adjusting pump (OPAP), made by Balance Ophthalmics, took effect on October 1, opening the door for Medicare-age patients — who make up a large share of the glaucoma population — to access the device. The OPAP consists of pressure-sensing goggles connected to a compact pump that uses negative pressure to counteract rising IOP during sleep.
The device is FDA-indicated for patients with IOP of 21 mm Hg or higher who have already tried other treatments. Clinicians describe it as a valuable adjunctive therapy, particularly for patients who are slowly progressing despite medications or prior surgery. A wireless-enabled version received FDA 510(k) clearance in 2026 and is expected to launch later this year.
By the Numbers
Why it matters: Nocturnal IOP spikes are a known but hard-to-treat risk factor for glaucoma progression. With Medicare coverage now in place, this non-pharmacological, non-surgical option could meaningfully expand treatment access for millions of older Americans managing glaucoma.
